Short-term responses to high-dose inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease with a fractional nitric oxide concentration over 35 parts per billion: A single-centre pre–post study
Open Access
- 6 October 2020
- journal article
- Published by Heighten Science Publications Corporation in Archives of Asthma, Allergy and Immunology
- Vol. 4 (1), 012-017
- https://doi.org/10.29328/journal.aaai.1001020
Abstract
Introduction: There is currently no strategy for identifying chronic obstructive pulmonary disease (COPD) patients whose pulmonary function could benefit from inhaled corticosteroids. We investigated whether a 28-day regime of inhaled corticosteroids improved pulmonary function test results among COPD patients with a fractional exhaled nitric oxide concentration > 35 parts per billion. Methods: This single-centre one-arm pre–post trial included COPD patients with a fractional exhaled nitric oxide concentration > 35 parts per billion treated at our institution from September 2018 to August 2019. Patients were administered budesonide (200 μg, 8 puffs daily) for 28 days. The primary outcome measure was the difference between the forced expiratory volume in 1 s (FEV1) at baseline and after 28 days of inhaled corticosteroid treatment. Secondary outcomes included differences in COPD Assessment Test scores, %FEV1, and that between the percent forced vital capacity (%FVC) at baseline and after 28 days of treatment. Results: Twenty patients completed the 28-day inhaled corticosteroid regime. The mean difference in FEV1 between day 1 and day 28 was 340 mL (95% confidence interval: −100 to 770 mL; p = 0.122). The mean differences in secondary outcomes were: %FVC, −0.16% (95% confidence interval [CI]: −2.84 to 2.53%; p = 0.905); %FEV1, 1.63% (95%CI: −4.56 to 7.81%; p = 0.589); COPD Assessment Test score, −2.50 (95%CI: −5.72 to 0.72; p = 0.121). Conclusion: The 28-day course of inhaled corticosteroids yielded no significant difference in FEV1 for COPD patients with a fractional exhaled nitric oxide concentration > 35 parts per billion. Trial registration: University Hospital Medical Information Network Center, UMIN000034005. Registered 3 September 2018, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000038557Keywords
This publication has 24 references indexed in Scilit:
- Asthma outcomes: BiomarkersJournal of Allergy and Clinical Immunology, 2012
- An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical ApplicationsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker?Frontiers in Pharmacology, 2011
- Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)European Respiratory Journal, 2008
- International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence studyThe Lancet, 2007
- Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatmentEuropean Respiratory Journal, 2006
- ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005American Journal of Respiratory and Critical Care Medicine, 2005
- Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary diseaseThorax, 2005
- Sputum Eosinophilia Predicts Benefit from Prednisone in Smokers with Chronic Obstructive BronchitisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment.American Journal of Respiratory and Critical Care Medicine, 1997